Augmented Virtual Reality for Reducing Pain, Stress, Anxiety and Improve Self Efficacy in Adult Cancer Patients Undergoing Chemotherapy in The West Bank

NCT07152938 | Completed

• 1 other identifier: AAUP-AVR-ONCO-2025
• Study Type: interventional
• Target: 150
• Locations: 1 country
• Sites: 3

Brief Summary

The main purpose of this study is to examine the effect of using AVR on pain, stress, anxiety, and SE among adult cancer patients undergoing chemotherapy in the West Bank hospitals in Palestine. The main questions it aims to answer are:

1. 1.What is the effect of AVR therapy on pain levels score compared with routine care during chemotherapy session among cancer patients?
2. 2.What is the effect of AVR therapy on the stress levels compared with routine care during chemotherapy session among cancer patients?
3. 3.What is the effect of AVR therapy on the anxiety compared with routine care during chemotherapy session among cancer patients?
4. 4.What is the effect of AVR therapy on the general SE compared with routine care during chemotherapy session among cancer patients?

Conditions

Cancer and Chemotherapy Related Anemia; Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma)

Keywords

Augmented Virtual Reality; Pain Management; Stress; Anxiety; Self-Efficacy; Chemotherapy; Palestine

Outcome Measures

Primary Outcomes (1)

• Change in pain intensity during chemotherapy

  Pain intensity will be measured using the Numeric Pain Rating Scale (NPRS). The NPRS is an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable). Higher scores indicate greater pain intensity. The outcome will be the change in NPRS score from immediately before to immediately after the chemotherapy session, comparing the AVR intervention group with the control group.

  Immediately before chemotherapy and immediately after the session (June 2023 - September 2023).

Secondary Outcomes (3)

• Change in self-efficacy during chemotherapy

  Immediately before chemotherapy and immediately after the session (June 2023 - September 2023).

• Change in perceived stress during chemotherapy

  Immediately before chemotherapy and immediately after the session (June 2023 - September 2023).

• Change in anxiety symptoms during chemotherapy

  Immediately before chemotherapy and immediately after the session (June 2023 - September 2023).

Study Arms (2)

Control Group (Standard Chemotherapy Care)

NO INTERVENTION

the control group participated in routine sessions without AVR. Patients were admitted to the daycare unit, where a cannula was applied. The nurse then followed the doctor's order for the type of medication that would be given to the patient. Subsequently, the patients filled out the questionnaire at the posttest.

AVR Group

EXPERIMENTAL

Patients receive standard chemotherapy care plus Augmented Virtual Reality (AVR) distraction sessions during chemotherapy infusion.

Behavioral: AVR Group (Chemotherapy + AVR)

Interventions

AVR Group (Chemotherapy + AVR) BEHAVIORAL

the intervention group received AVR before they started treatment and during the session. The researcher administered the posttest questionnaire The questionnaire assessed immediately after finishing AVR. Participants informed not to discuss AVR with each other's, as the researcher explained to the participants the purpose of the study and their participation will not affect their care or treatment

AVR Group

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Adult patients aged 18-60 years undergoing chemotherapy for breast or colon cancer.
• Stage I or II cancer, as defined by the study protocol.
• Manageable levels of pain, anxiety, and stress, appropriate for participation in the intervention.

You may not qualify if:

• Age over 60 years.
• Cancer types other than breast or colon cancer.
• Severe pain, anxiety, or stress that could interfere with participation or require intensive care beyond the study scope.

Sponsors & Collaborators

• Arab American University (Palestine): lead

Study Sites (3)

Jenin governmental hospital

Jenin, 00970, Palestinian Territories

Location

AL-Watni governmental hospital

Nablus, 00970, Palestinian Territories

Location

Thabet Thabet governmental hospital

Tulkarm, 00970, Palestinian Territories

Location

MeSH Terms

Conditions

Neoplasms; Colonic Neoplasms; Breast Neoplasms; Lymphoma; Multiple Myeloma; Agnosia; Anxiety Disorders

Interventions

Drug Therapy

Condition Hierarchy (Ancestors)

Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Neoplasms by Histologic Type; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Neoplasms, Plasma Cell; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemorrhagic Disorders; Perceptual Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Mental Disorders

Intervention Hierarchy (Ancestors)

Therapeutics

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: academic lecturer

Model Details: participants randomly assigned to either the intervention group(augmented virtual reality sessions)or the other control group( standard care)

Study Record Dates

• First Submitted: August 26, 2025
• First Posted: September 3, 2025
• Study Start: June 1, 2023
• Primary Completion: September 30, 2023
• Study Completion: October 30, 2023
• Last Updated: September 15, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

PA (3)